China Resources Double-Crane Pharmaceutical Co., Ltd. approved the proposal of nominating Zhang Kejian as Independent Director at directorate meeting held on January 22, 2016.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.33 CNY | -2.07% |
|
-4.78% | +9.30% |
Jun. 14 | CR Double-Crane Pharmaceutical Gets Certificate to Market Low-Calcium Dialysis Solution | MT |
May. 27 | CR Double-Crane Pharmaceutical's Unit Gets Nod for Phloroglucinol Injection | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.30% | 2.92B | |
+53.73% | 803B | |
-6.37% | 351B | |
+18.46% | 324B | |
+11.23% | 303B | |
+16.96% | 243B | |
+2.25% | 228B | |
+11.15% | 217B | |
+6.64% | 164B | |
-3.35% | 155B |
- Stock Market
- Equities
- 600062 Stock
- News China Resources Double-Crane Pharmaceutical Co.,Ltd.
- China Resources Double-Crane Pharmaceutical Co., Ltd. Approves to Nominates Zhang Kejian as Independent Director